BioCentury
ARTICLE | Product Development

Pfizer dips into translational regulation for cancer with eFFECTOR deal

Pfizer’s deal with eFFECTOR points to translational regulators as an emerging target source

January 9, 2020 1:03 PM UTC
Updated on Feb 25, 2020 at 9:45 PM UTC

eFFECTOR’s deal with Pfizer is the latest indication that translational control elements are a promising, emerging source of new drug targets. The companies teamed up to develop small molecule inhibitors of the translation initiation complex subunit eIF4E to treat cancer.

eFFECTOR Therapeutics Inc. will receive $15 million up front and up to $429 million in R&D funding and development and sales milestones through the licensing and collaboration agreement...